The Secukinumab market is gaining momentum as the prevalence of chronic autoimmune diseases like plaque psoriasis and psoriatic arthritis continues to climb worldwide. With its proven effectiveness in targeting interleukin-17A (IL-17A), secukinumab i...

Markdown supported · ⌘↵ to post
No responses yet.